{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:23:32Z","timestamp":1790720612002,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pharma.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:17:10Z","timestamp":1668197830000},"page":"596-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Appropriateness of proton pump inhibitors prescription in patient admitted to hospital: An observational study"],"prefix":"10.1016","volume":"81","author":[{"given":"P.","family":"Gendre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mocquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Huon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.11.003_bib0160","series-title":"Utilisation des inhibiteurs de la pompe \u00e0 protons (IPP); \u00c9tude observationnelle \u00e0 partir des donn\u00e9es du SNDS 2015 [Internet]","author":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament","year":"2018"},{"key":"10.1016\/j.pharma.2022.11.003_bib0165","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharma.2022.11.003_bib0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11894-008-0045-4","article-title":"Potential adverse effects of proton pump inhibitors","volume":"10","author":"Cot\u00e9","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.pharma.2022.11.003_bib0175","first-page":"1665","article-title":"Proton pump inhibitors (PPI): may be not as harmless as believed","volume":"11","author":"Reinberg","year":"2015","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.pharma.2022.11.003_bib0180","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.003_bib0185","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","article-title":"Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies","volume":"124","author":"Yu","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.pharma.2022.11.003_bib0190","series-title":"Recommandations HAS [Internet]","year":"2009"},{"key":"10.1016\/j.pharma.2022.11.003_bib0195","series-title":"Haute autorit\u00e9 de sant\u00e9. R\u00e9f\u00e9rentiels profesionnels. Indication \u00e0 vis\u00e9e diagnostique de l\u2019endoscopie digestive haute en pathologie oeso gastro duod\u00e9nale de l\u2019adulte \u00e0 l\u2019exclusion de l\u2019echoendoscopie et l\u2019ent\u00e9roscope. (Internet)","first-page":"7","author":"Dupas","year":"2001"},{"key":"10.1016\/j.pharma.2022.11.003_bib0200","doi-asserted-by":"crossref","unstructured":"I. Marie, A. Moutot, A. Tharrasse, M.-F. Hellot, S. Robaday, F. Herv\u00e9, H. L\u00e9vesque. Validity of proton pump inhibitors\u2019prescriptions in a department of internal medicine. Rev Med Interne 28:86-93. DOI: 10.1016\/j.revmed.2006.09.030.","DOI":"10.1016\/j.revmed.2006.09.030"},{"key":"10.1016\/j.pharma.2022.11.003_bib0205","unstructured":"Macaignes G. \u00c9valuation des pratiques professionnelles sur la pertinence des prescriptions des IPP dans un centre hospitalier g\u00e9n\u00e9ral. SNFGE.org, https:\/\/www.snfge.org\/content\/evaluation-des-pratiques-professionnelles-sur-l.(accessed 25 May 2020)."},{"key":"10.1016\/j.pharma.2022.11.003_bib0210","unstructured":"Villiet M, Giraudon L, Combescure C. Bon usage des inhibiteurs de la pompe \u00e0 protons: \u00e9tude observationnelle desprescriptions en milieu hospitalier. J Pharm Clin; 28(3):135-40."},{"key":"10.1016\/j.pharma.2022.11.003_bib0215","unstructured":"Dhelens C. Evaluation du bon usage des IPP dans un Centre Hospitalier g\u00e9n\u00e9ral, https:\/\/www.synprefh.org\/files\/archives\/hopi2013_poster%20001.pdf.(2013, accessed 20 October 2022)."},{"key":"10.1016\/j.pharma.2022.11.003_bib0220","first-page":"1","article-title":"Over prescribing proton pump inhibitors","volume":"336","author":"Forgacs Ian","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2022.11.003_bib0225","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","volume":"56","author":"Abraham","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2022.11.003_bib0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharma.2022.11.003_bib0235","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 C de la T. Rapport d\u2019\u00e9valuation des inhibiteurs de la pompe \u00e0 protons (sp\u00e9cialit\u00e9s et g\u00e9n\u00e9riques), https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/rapport_reevaluation_ipp_avisdef_cteval493.pdf.(November 2020, accessed 20 October 2022)."},{"key":"10.1016\/j.pharma.2022.11.003_bib0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2020.02.020","article-title":"The impact of proton pump inhibitors on levothyroxine absorption: the good, the bad and the ugly","volume":"76","author":"Guzman-Prado","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pharma.2022.11.003_bib0245","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/pds.3881","article-title":"The potential drug-drug interaction between proton pump inhibitors and warfarin","volume":"24","author":"Henriksen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pharma.2022.11.003_bib0250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11886-011-0233-y","article-title":"Clopidogrel and PPI interaction: clinically relevant or not?","volume":"14","author":"Harrison","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pharma.2022.11.003_bib0255","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s10620-011-2007-1","article-title":"Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature","volume":"57","author":"Gerson","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharma.2022.11.003_bib0260","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2022.11.003_bib0265","series-title":"S\u00e9curit\u00e9 Sociale. Les prescriptions d\u2019IPP - Rapport de la Commission des comptes de la S\u00e9curit\u00e9 Sociale [Internet]","author":"Chevreul","year":"2009"},{"key":"10.1016\/j.pharma.2022.11.003_bib0270","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s10620-015-3642-8","article-title":"The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study","volume":"60","author":"Kelly","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharma.2022.11.003_bib0275","unstructured":"C Jehanno, Baril J, Chamberland C. Suivi de la mesure de remboursement des inhibiteurs de la pompe \u00e0 protons (IPP). Qu\u00e9bec (QC): Institut national d\u2019excellence en sant\u00e9 et en services sociaux, https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Rapports\/Medicaments\/INESSS_Suivi_de_la_mesure_de_remboursement_des_IPP.pdf.(2014, accessed 20 October 2022)."},{"key":"10.1016\/j.pharma.2022.11.003_bib0280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases\u2013A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2022.11.003_bib0285","series-title":"Thesaurus des interactions medicamenteuses","first-page":"257","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament","year":"2020"},{"key":"10.1016\/j.pharma.2022.11.003_bib0290","first-page":"e007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pharma.2022.11.003_bib0295","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s10620-009-0851-z","article-title":"Omeprazole induces gastric permeability to digoxin","volume":"55","author":"Gabello","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharma.2022.11.003_bib0300","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","article-title":"Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2022.11.003_bib0305","first-page":"1379","article-title":"Analysis of combined effect of CYP2C19 genetic polymorphism and proton pump inhibitors coadministration on trough concentration of Voriconazole","volume":"14","author":"Mafuru","year":"2021","journal-title":"Pharmacogenomics Pers Med"},{"key":"10.1016\/j.pharma.2022.11.003_bib0310","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:35Z","timestamp":1757720255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003450922001468"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriateness of proton pump inhibitors prescription in patient admitted to hospital: An observational study","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}